OTC Pre-Market Testing Could Lead To Safer Widespread Usage – Ganley
This article was originally published in The Tan Sheet
Executive Summary
Distribution of an OTC drug within a limited geographic region "during the approval process" could help identify and eliminate possible safety issues before widespread national availability, Center for Drug Evaluation & Research Division of OTC Drug Products Director Charles Ganley, MD, asserted
You may also be interested in...
Label Comprehension Studies Must Account For Drugs’ Complexity – Bull
The science behind creating OTC labeling and label comprehension studies needs to be improved to account for the increasing complexity of nonprescription drugs and their indications, stated Center for Drug Evaluation & Research Office of Drug Evaluation V Director Jonca Bull, MD
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands